#United States #New York #Securities Fraud #Pomerantz Law #Edgewise Therapeutics

Pomerantz Law Firm Investigates Edgewise Therapeutics

On July 31, 2025, Pomerantz LLP announced its ongoing investigation into claims made by investors of Edgewise Therapeutics, Inc., which trades under the NASDAQ symbol EWTX. Investors are encouraged to reach out to the firm for guidance and support, especially those who may have suffered losses due to the company’s conduct.

The investigation centers around allegations that Edgewise and some of its officials and directors may have participated in activities constituting securities fraud or other unethical business practices. The firm specializes in corporate, securities, and antitrust class litigation and has a longstanding reputation for advocating on behalf of defrauded investors.

Recent Developments

A significant trigger for the investigation was a press release issued by Edgewise on June 26, 2025. The announcement included results from clinical trials for their lead product candidate, sevasemten, aimed at treating Becker and Duchenne muscular dystrophies. While Edgewise portrayed the findings as promising, they also communicated that the U.S. Food and Drug Administration (FDA) found the data from these trials inadequate for fast-tracking approval. Following this announcement, Edgewise’s stock saw a dramatic decline, falling by $1.27 per share, or approximately 8.86%, to settle at $14.33.

This abrupt decrease in stock price raised concerns among investors, and many are left questioning the true nature of the data disclosed by the company. The essence of the lawsuit aims to determine whether Edgewise misled investors about the efficacy and regulatory outlook of sevasemten.

About Pomerantz LLP

Pomerantz LLP has operated for over 80 years, extending its impact across major metropolitan areas, including New York, Chicago, London, and Paris. The firm has achieved numerous multimillion-dollar settlements for its clients and proudly carries the legacy of its founder, Abraham L. Pomerantz, regarded as a pioneer in the field of class action lawsuits. Pomerantz LLP remains committed to representing investors and victims of securities fraud and corporate misconduct.

They offer potential claimants the opportunity to join a class action, which stands as a collective effort to hold wrongdoers accountable. Danielle Peyton, an attorney at Pomerantz, is handling inquiries related to this investigation, and interested individuals are urged to reach out directly to her for more information.

To conclude, the stakes for investors in Edgewise Therapeutics are high as developments continue to unfold, and the outcomes of this investigation could have profound implications for both them and the company moving forward.

For further inquiries or to discuss participation in the class action, contact Danielle Peyton at Pomerantz LLP via email or telephone.

_Contact: Danielle Peyton, Pomerantz LLP, [email protected], 646-581-9980 ext. 7980_